BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:05 PM
 | 
Sep 23, 2008
 |  BC Extra  |  Company News

Genzyme gives update on filings

Genzyme provided an update on three compounds under FDA review: Mozobil plerixafor, Myozyme alglucosidase and Synvisc-One. FDA accepted for filing and granted Priority Review to an NDA for Mozobil to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in patients with lymphoma...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >